Company: RGNT
Filing Date: 2025-01-27
Form Type: DRS/A
Source: 0001213900-25-006676
Chunk: 226

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-27
Form: DRS/A
Chunk 226
---
 fees
and expenses of its legal counsel in connection with the offering in an amount not to exceed $125,000, the fees and expenses related to
the use of Ipreo’s book building, prospectus tracking and compliance software for the offering in the amount of $29,500, up to $15,000
for background checks of our officers and directors, the costs associated with bound volumes of the public offering materials as well
as commemorative mementos and lucite tombstones in an amount not to exceed $3,000, data services and communications expenses up to $10,000,
the actual accountable “road show” expenses up to $10,000 and the costs of market making and trading and clearing firm settlement
expenses up to $30,000; provided however that the aggregate accountable expenses reimbursement will not exceed $175,000.

We expect that the expenses
of this offering payable by us, not including underwriting discounts and commissions, will be approximately $ .

Representative’s Warrants

We have agreed to issue to
the Representative, upon the consummation of this offering, warrants to purchase up to an aggregate of shares
of our Ordinary Shares (representing 5.0% of the Ordinary Shares sold in this offering, including any Ordinary Shares sold upon exercise
of the Representative’s over-allotment option), or the Representative’s Warrants. The Representative’s Warrants are
exercisable at a per share price equal to (representing 125.0% of the public offering price per share in this offering). The Representative’s
Warrants are exercisable at any time and from time to time, in whole or in part, during the four and one-half (4.5) year period commencing
180 days from the commencement of sales of the securities in this offering. The Representatives Warrants will provide for registration
rights (including a one-time demand registration right and unlimited piggyback rights) and customary anti-dilution provisions (for stock
dividends and splits and recapitalizations) consistent with FINRA Rule 5110, and further, the number of shares underlying the Representative’s
Warrants shall be reduced if necessary to comply with FINRA rules or regulations.

<div align='center'>137</div>

The Representative’s
Warrants are deemed underwriter compensation by FINRA and are therefore subject to a 180-day lock-up pursuant to FINRA Rule 5110(g)(1).
The Representative (or permitted assignees under Rule 5110